- Pressure BioSciences was described as an integral part of women’s cancer research efforts during a presentation last month at the International Gynecologic Cancer Society conference in Brazil
- The company’s patented pressure cycling technology provided a key link in a trio of procedures for analyzing biopsied cells
- Gynecologic cancers are diagnosed in the United States at a rate of nearly 100,000 women per year, and the global gynecological cancer drug market is expected to generate revenues of more than $41.8 billion by 2026
A new, novel workflow for the analysis of proteins from cancer biopsy samples was recently disclosed at a major international gynecologic cancer meeting. This innovative workflow is expected to markedly enhance cancer diagnosis, prognosis and effective treatment therapies. The revelation of this new workflow has augmented the reputation of Pressure BioSciences Inc. (OTCQB: PBIO) amid the modern science rush to build better precision medicine for malignancies that claim hundreds of thousands of lives each year in the United States alone (http://ibn.fm/vawZS).
Human biology is complex, but scientific advances in the field of big data analysis have provided remarkably advanced tools for attempting repairs on the constellation of minuscule pieces of the human machine that may break down.
Efforts to develop an optimal means of analyzing proteins from cancer biopsy samples led one group of top gynecologic researchers to a new, innovative workflow that utilizes Pressure BioSciences’ patented pressure cycling technology (PCT) platform as the bridging mechanism in a process that begins with Leica Microsystems’ laser microdissection (LMD) platform and ends with comprehensive analysis on a ThermoFisher Scientific mass spectrometry (MS) instrument.
Pressure BioSciences’ PCT platform, as an integral part of the analytical trio, prepares the excised cells for micro-scale quantitative proteomics and phosphoproteomics – the large-scale study of proteins and their phosphorylation-based signaling networks – by provoking rapid and efficient high-quality cellular protein release and preparation from the biopsy samples. The entire sample preparation process is done in the company’s proprietary Barocycler 2320EXT system.
The researchers presented an explanation of their working process in searching for ways to combat gynecological cancers during a core session of the annual International Gynecologic Cancer Society (“IGCS”) conference last month in Rio de Janeiro, Brazil. Dr. Larry Maxwell, a gynecologic oncologist and the OB-GYN chairman at Northern Virginia’s Inova Fairfax Hospital, described the PCT-based Barocycler system technology provided by Pressure BioSciences as “an essential requirement for our novel workflow in meeting our goals” in his presentation to the IGCS.
“The conventional use of chemotherapy in ovarian cancer treatment is being rapidly replaced by biologic therapeutics that target the cancer (the ‘seed’) and also the micro-environment (the ‘soil’) in which it grows,” Maxwell stated in a news release (http://ibn.fm/fo6x7). “Being able to collect small tissue specimens and characterize them across multiple genomic and proteomic platforms will enable us to markedly enhance our ability to develop companion diagnostics and prognostics as well as identify targets for future therapeutic strategies.”
Protein chemist Dr. Thomas Conrads, the senior director of women’s health research at the Inova Women’s Hospital, added, “We believe that the insights we gain from applying this novel workflow will result in significant improvements in the clinical management of gynecologic cancer.”
Gynecologic cancers are diagnosed at a rate of nearly 100,000 women per year in the United States (http://ibn.fm/koVZR). Aurora Healthcare estimates that more than 30,000 of those patients die each year (http://ibn.fm/EezJZ). Publication The Pharma Letter, citing analysis by Persistence Market Research Report, states that the worldwide market for gynecological cancer drugs is expected to expand at a CAGR of 6.2 percent between 2018 and 2026, generating revenues of more than $41.8 billion (http://ibn.fm/aeE8t), with most of the costs led by the United States. The importance of effective therapies in terms of life-saving measures and product costs is apparent, and it serves as an indicator of PBIO technology’s potential attractiveness to other research labs.
Pressure BioSciences continues adding a number of significant achievements to underscore the reputation of its technology. Recently, the company announced an agreement with a world-renowned, multibillion-dollar biotherapeutics firm that will use PBIO’s proprietary BaroFold(TM) technology to improve the manufacture of a protein drug (http://ibn.fm/KaqJ1). Protein-based therapeutics are a growing part of the global health care industry, which is projected to reach nearly $249 billion in revenues by next year, according to Research and Markets analysis (http://ibn.fm/RIKAI).
For more information, visit the company’s website at www.PressureBioSciences.com
NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.